A new study suggests that a simple blood test has revealed promising results for the early detection of Alzheimer’s disease. The study was published in the Journal of the American Medical Association (JAMA) ‘Neurology’. It focuses on phosphorylated tau, or p-tau217, a key protein associated with Alzheimer’s pathology. Unlike current methods involving brain scans or spinal taps, this blood test demonstrated up to 96 percent accuracy in identifying elevated levels of beta-amyloid and up to 97 percent accuracy in identifying p-tau217.
Biomarker breakthrough
Professor Nicholas Ashton from the University of Gothenburg, Sweden, conducted this study to test for p-tau217, a biomarker of Alzheimer’s. His study’s findings suggest that this Alzheimer’s blood test is as accurate as advanced techniques, such as cerebrospinal fluid tests and brain scans. Hence, it can detect Alzheimer’s disease pathology in the brain.
According to the study, the Alzheimer’s blood test, ALZpath pTau217 assay, is currently available for research use only. However, it is expected to be available for clinical use soon. The test’s commercial developer, ALZpath, estimates a price range between $200 and $500.
Patient management
The study’s findings indicate that the Alzheimer’s blood test could play a crucial role in guiding treatment decisions. Specifically, the test demonstrated high accuracy in identifying tau pathology in individuals with elevated beta-amyloid levels. This insight may aid in personalized treatment strategies. Thus, certain therapies targeting beta-amyloid may be less effective in patients with advanced tau pathology.
Clinical efficiency
Data from the study, which included 786 participants, showcased the blood test’s efficiency in reducing the need for costly and high-demand examinations. A blood test, combined with clinical examination, could provide definitive decisions in 80 percent of cases with early signs of dementia. The potential for routine blood tests for Alzheimer’s disease in individuals over 50 could revolutionize early detection and management strategies.
Although the blood test in this study was highly accurate in predicting whether someone has key characteristics of Alzheimer’s disease in their brain, not everyone with those characteristics will go on to develop the disease.
Moreover, the p-tau blood test is specific for Alzheimer’s disease. Therefore, if someone tests negative but is showing signs of cognitive impairment, this test could not determine other possible causes of their symptoms, such as vascular dementia or Lewy body dementia.
Read: Saudi launches first oncology pharmaceutical plant
Expert perspectives
Experts in the field praised the study’s findings, emphasizing the importance of early detection before symptoms manifest. However, some experts raised concerns about the psychological impact on individuals who test positive for Alzheimer’s pathology but may never develop symptoms. They stress the importance of careful consideration and consultation with healthcare professionals.
The study’s results provide hope for a more accessible and cost-effective method of Alzheimer’s screening. The potential for routine Alzheimer’s blood tests could democratize access to early detection. It allows for timely interventions and the development of disease-modifying therapies. With ongoing advancements in Alzheimer’s research, this blood test represents a significant step toward proactive management and prevention of the devastating disease.
For more news on health, click here.
